Drugmakers plan to raise US prices on at least 350 medications: Report
Rising costs hit working families hardest while Washington debates spending priorities.
prices rise, so government must tighten its grip. But it skips a basic question. If drugmakers “pledged” better deals under new policies, why is the market still built to reward higher list prices and backroom rebates?
New Republican Times Editorial Board
The cost of at least 350 drugs in the U.S. are expected to rise in 2026, according to a new analysis, despite many of the drugmakers pledging to offer more favorable prices under new Trump administration policies.
Original source:
Read at Wsav-tvHow We See It
New Republican Times Editorial Board
prices rise, so government must tighten its grip. But it skips a basic question. If drugmakers “pledged” better deals under new policies, why is the market still built to reward higher list prices and backroom rebates?
Conservatives should be clear-eyed about what’s broken. Middlemen and opaque pricing games thrive in a system where patients pay at the counter while insurers and PBMs negotiate in private. That is not a free market. It’s a maze that erodes public trust, punishes the uninsured, and hides who’s really taking the spread.
An America First approach starts with price transparency, real competition, and cracking down on anti-competitive behavior, not blank checks or sweeping controls. The principle at stake is fairness for patients and accountability in healthcare, so prices reflect value, not leverage.
Commentary written with AI assistance by the New Republican Times Editorial Board.